Aymeric Dugray

Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France.

Wittycell SAS engages in the research and development, manufacturing, and sale of therapeutic and prophylactic vaccines. It offers novel adjuvant products against infectious diseases and cancer. The company was founded in August 2005 and is headquartered in Reims, France.

Nokad is a biotech start up created in January 2004 by three experienced scientists with scientific medical, pharmaceutical and business skills. The head office and the laboratory are located at Genopole d'Evry ( France ). Nokad developed a new technology that allows the inactivation of secreted proteins in vivo in 6 months, whatever the species required. Nokad was selected for pertinence and high potential for success by the Aventis-Institut de France Foundation in 2003 (Tremplins 2003). Nokad is supported by Genopole Entreprises. Recent Highlights Anticipated Highlights 8 secreted targets efficiently neutralized by the protein-function-KO technology, with Rat and mice protein-Knock-Out successfully obtained. Two new patents filled in 2006 and 2007, in thrombocytopenia treatment and in a Erythropoietin-mice and -rat model. Validation of a vaccination strategy for hypertriglyceridemia in 2009. Three contracts with pharmaceutical companies (Sanofi-Aventis, GSK, Servier). Multiple collaborative programs with pharmaceutical companies and academic groups. Corporate Mission The main objective of NOKAD is to follow the development and optimization of their technology platform for in vivo target validation. A secondary objective is the development of new therapeutic options based on vaccination against endogenous targets. Both side of their approach used the same platform set up since 2004. This innovative tool changes the way complex biologic questions can be solved in a short time. Furthermore, the proprietary protein-functional-Knock-Out technology allows testing the therapeutic options in all mammalians species before entering human clinical trials. This new way of thinking can potentially reduce the high failure rate of pharmaceutical drugs following their entry into clinical trials.